OIM
IBRX icon

Oracle Investment Management’s ImmunityBio IBRX Stock Holding History

Oracle Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-315,322
Closed -$1.57M – 27
2022
Q3 		$1.57M Buy
+315,322
New +$1.44M 0.89% 12
2022
Q2 		– Sell
-400,013
Closed -$2.24M – 34
2022
Q1 		$2.24M Buy
+400,013
New +$2.45M 0.44% 17

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Oracle Investment Management's IBRX Position: Q4 2022 in Review

Oracle Investment Management sold out of ImmunityBio (IBRX) in Q4 2022, closing a stake of 315,322 shares — an estimated $1.57M sold.

Oracle Investment Management first reported a position in IBRX in Q1 2022 and held it in 2 quarters. The position peaked at $2.24M in Q1 2022. 139 funds tracked by Wall St. Rank hold IBRX as of Q4 2022.

  • Oracle Investment Management reported no remaining ImmunityBio position as of Q4 2022 after selling out during the quarter.
  • Oracle Investment Management sold 315,322 ImmunityBio shares in Q4 2022, an estimated $1.57M.
  • Oracle Investment Management first reported a position in ImmunityBio in Q1 2022 and held it in 2 quarters.
  • Oracle Investment Management's ImmunityBio position peaked at $2.24M in Q1 2022.
  • 139 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2022.

Based on Oracle Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.